Fingerprint
Dive into the research topics of 'A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors
Alex A. Adjei, Patricia LoRusso, Antoni Ribas, Jeffrey A. Sosman, Anna Pavlick, Grace K. Dy, Xiaofei Zhou, Esha Gangolli, Michelle Kneissl, Stephanie Faucette, Rachel Neuwirth, Viviana Bózon
Research output: Contribution to journal › Article › peer-review
14
Scopus
citations